

2008 Physician Quality Reporting Initiative Patient-Level Measures

Each measure specified in the 2008 PQRI program includes a reporting frequency requirement for each denominator-eligible patient seen during the reporting period (January 1 – December 31, 2008). Measure specification instructions limit the frequency of reporting necessary in certain circumstances (such as for patients with chronic illness for whom a particular process of care is provided periodically). The following list is a subset of the 2008 measures for which the reporting frequency is a minimum of once during the reporting period.

Measure Number	Measure Title
1	Hemoglobin A1c Poor Control in Type 1 or 2 Diabetes Mellitus
2	Low Density Lipoprotein Control in Type 1 or 2 Diabetes Mellitus
3	High Blood Pressure Control in Type 1 or 2 Diabetes Mellitus
4	Screening for Future Fall Risk
5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
6	Oral Antiplatelet Therapy Prescribed for Patients with Coronary Artery Disease
7	Beta-blocker Therapy for Coronary Artery Disease Patients with Prior Myocardial Infarction (MI)
8	Heart Failure: Beta-blocker Therapy for Left Ventricular Systolic Dysfunction
12	Primary Open Angle Glaucoma: Optic Nerve Evaluation
14	Age-Related Macular Degeneration: Dilated Macular Examination
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
19	Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older
41	Osteoporosis: Pharmacologic Therapy
47	Advance Care Plan
48	Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older
49	Characterization of Urinary Incontinence in Women Aged 65 Years and Older
50	Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy
53	Asthma: Pharmacologic Therapy
64	Asthma Assessment
67	Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow
68	Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy
69	Multiple Myeloma: Treatment with Bisphosphonates
70	Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry
71	Hormonal Therapy for Stage IC - III ER/PR Positive Breast Cancer
72	Chemotherapy for Stage III Colon Cancer Patients
73	Plan for Chemotherapy Documented Before Chemotherapy Administered
74	Radiation Therapy Recommended for Invasive Breast Cancer Patients who have Undergone Breast Conserving Surgery
77	Assessment of GERD Symptoms in Patients Receiving Chronic Medication for GERD
78	Vascular Access for Patients Undergoing Hemodialysis
79	Influenza Vaccination in Patients with End Stage Renal Disease (ESRD)
83	Testing of Patients with Chronic Hepatitis C (HCV) for Hepatitis C Viremia
84	Initial Hepatitis C RNA Testing
85	HCV Genotype Testing Prior to Therapy
86	Consideration for Antiviral Therapy in HCV Patients
87	HCV RNA Testing at Week 12 of Therapy
88	Hepatitis A and B Vaccination in Patients with HCV
89	Counseling Patients with HCV Regarding Use of Alcohol

2008 Physician Quality Reporting Initiative
Patient-Level Measures

Measure Number	Measure Title
90	Counseling of Patients Regarding Use of Contraception Prior to Starting Antiviral Therapy
101	Appropriate Initial Evaluation of Patients with Prostate Cancer
103	Review of Treatment Options in Patients with Clinically Localized Prostate Cancer
108	Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis
110	Influenza Vaccination for Patients ≥ 50 Years Old
111	Pneumonia Vaccination for Patients 65 years and Older
112	Screening Mammography
113	Colorectal Cancer Screening
114	Inquiry Regarding Tobacco Use
115	Advising Smokers to Quit
117	Dilated Eye Exam in Diabetic Patient
118	Angiotensin Converting Enzyme Inhibitor (ACE) or Angiotensin Receptor Blocker (ARB) Therapy for Patients with Coronary Artery Disease and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD)
119	Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients
120	ACE Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy in Patients with CKD
121	Chronic Kidney Disease (CKD): Laboratory Testing (Calcium, Phosphorus, Intact Parathyroid Hormone (iPTH) and Lipid Profile)
126	Diabetic Foot and Ankle Care, Peripheral Neuropathy: Neurological Evaluation
127	Diabetic Foot and Ankle Care, Ulcer Prevention: Evaluation of Footwear
128	Universal Weight Screening and Follow-Up
133	Screening for Cognitive Impairment
134	Screening for Clinical Depression